Pay in 4 interest-free payments of $7.44 Learn more
Ships within 48 hours · Estimated delivery Sep 3 - Sep 8
With the success of landmark cardiovascular outcome trials on glucagon-like peptide-1 receptor agonist (GLP-1RA) and sodium-glucose cotransporter-2 inhibitors (SGLT2i) [10], this has transformed the landscape of cardiometabolic disease management [11]
Integration of pharmacogenomics, metabolomics and microbiomics: Path to personalized metformin therapy Until recently, personalized medicine in T2D has predominantly focused on variation in DNA sequence
Weight Loss Surgery: What Patients Should Know in 2026 Oral GLP-1 medications are changing the weight loss conversation
Lipoprotein(a) is markedly more atherogenic than LDL: an apolipoprotein B-based genetic analysis
US$ 21.75
US$ 25.69
US$ 23.07
US$ 28.25
